Heron Therapeutics (HRTX) Stock Forecast: StockMap's 2-Week Call
HRTX stock forecast: StockMap's model leans Underperform on Heron Therapeutics for the two weeks after the Nov 19 close, toward HRTX trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 2 of 6 two-week windows on HRTX since Aug 21; by chance, a call on the same dates was right 58% of the time.
Heron Therapeutics last closed at $0.26, -3.70% on the session.
Against the IVW growth benchmark the position is -1.37% over the forecast window.
Heron Therapeutics' market cap is $50.02M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -27 (too close to call).
Where HRTX sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 3 bullish and 12 bearish.
Agreement across those insights is 80%.
44 daily calls for HRTX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Heron Therapeutics in the 2nd percentile on return on equity, where 100 is best.
Heron Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Heron Therapeutics as the 308th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Heron Therapeutics ranks 209th of 394 in the group, against a group median of -0.27.